ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BBNX / news
SIBN (52) IRMD (55) IART (19) KIDS (50) ⌘ Pro Terminal →

Why BBNX Stock dropped -5.07% Today — RQD Quant Desk Flash

$15.90 -5.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.72

Beta Bionics Inc. (BBNX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $910.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBNX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Beta Bionics Inc. (NASDAQ: BBNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $15.90 (-5.07% 1D, market cap $910.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BBNX ranks #563 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBNX compare to SIBN and IRMD in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), BBNX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 55.4%, and ROIC of -22.1%. By comparison, SIBN (SI-BONE Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M) and IRMD (iRadimed Corporation) posts a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBNX?
▼

Per BBNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674632), Beta Bionics Inc. generated $100.3M in revenue (+53.9% YoY), -$73.2M in net income, and -$56.2M in free cash flow against $328.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.73 (-1.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (9)Whales (6)SEC (11)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$34 Bull$14 Base$11 Bear
📬 FREE BBNX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBNX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY BBNX SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)

Altman Z-Score 12.82 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 55.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$17.69+0.3% Next Q
Q2 (-2Q)
41
Grade D$17.74+20.6% Next Q
Q3 (-1Q)
39
Grade E$21.39-25.7% Next Q
Current
36
Grade D-$15.90-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBNX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBNX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.02) and Max Pain ($16.70) forces dealer call-delta covering toward $34.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BBNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BBNX Stock dropped -5.07% Today — RQD Quant Desk Flash

Beta Bionics Inc. (BBNX) dropped -5.07% to $15.90, trading at 30% of its 52-week range ($8.8 – $32.71). Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 30% of its 52-week range ($8.8 – $32.71) with RSI-14 at 42.4 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.90 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 55.4% gross margin and $0 annual free cash flow.
Live BBNX Headlines & Catalysts
MARKET WIREBenzinga • 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBNX)

  • ✓Walkthrough of BBNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BBNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.58%📐 HORIZONTAL RANGE
2026-11-03O $17.58H $17.58L $15.90C $15.90VOL 1.07M
RES: $27.21SUP: $12.08SMA50: $19.02SMA200: $14.81
$24.58$20.36$16.14$11.92$7.70RES $27.21SUP $12.08$15.902026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBNX Butterfly Map → + Track BBNX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +53.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BBNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BBNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBNX)

Health Care Rank #563 of 1015 ⚔️ SIBN vs BBNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBNX vs. SIBN, IRMD, IART, KIDS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Beta Bionics Inc. (BBNX) ranks #563 by composite RQD confidence (36/100, grade D-) and #369 by equity capitalization ($910.6M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with BBNX at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BBNX ACTIVE
Beta Bionics Inc.
D- 36/100 — 55.4% -22.1% -5.07% $910.6M Benchmark Subject
SIBN
SI-BONE Inc.
D+ 52/100 — 79.6% -10.3% -4.76% $951.5M /sibn-vs-bbnx →
IRMD
iRadimed Corporation
D+ 55/100 48.8x 76.7% 37.7% +3.57% $980.5M /irmd-vs-bbnx →
IART
Integra LifeSciences Holdings Corporation
E 19/100 — 50.9% -35.0% +6.75% $992.0M /iart-vs-bbnx →
KIDS
OrthoPediatrics Corp.
D 50/100 — 73.1% -7.3% -1.42% $806.0M /kids-vs-bbnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674632 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Beta Bionics Inc. (BBNX) reported GAAP revenue of $100.3M (+53.9% vs. FY2024 revenue of $65.1M , and +735.8% cumulative change since FY2023) , GAAP net income of -$73.2M, operating cash flow of -$50.9M, and free cash flow of -$56.2M (-8.8% YoY). On the balance sheet, BBNX closed FY2025 with $328.7M in total assets against $0 in total debt (Altman Z-Score: 12.82, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $100.3M -$73.2M -$50.9M -$56.2M $328.7M —
FY2024 (FY) 2024-12-31 $65.1M -$54.8M -$48.3M -$51.7M $149.6M —
FY2023 (FY) 2023-12-31 $12.0M -$44.1M -$32.4M -$32.4M — —

3. BBNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Beta Bionics Inc. (NASDAQ: BBNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $15.90 (-5.07% 1D, market cap $910.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BBNX ranks #563 in composite RQD confidence.

How does BBNX compare to SIBN and IRMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BBNX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 55.4%, and ROIC of -22.1%. By comparison, SIBN (SI-BONE Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M) and IRMD (iRadimed Corporation) posts a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BBNX?

Per BBNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674632), Beta Bionics Inc. generated $100.3M in revenue (+53.9% YoY), -$73.2M in net income, and -$56.2M in free cash flow against $328.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BBNX trading relative to its 50-day, 200-day, and 52-week technical levels?

BBNX last traded at $15.90 (-5.07% on volume of 804,271 shares), positioning the stock -16.40% below its 50-day simple moving average ($19.02) and +7.36% above its 200-day simple moving average ($14.81). Across its 52-week range of $8.80 to $32.71, BBNX sits at the 29.7% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.91 to $17.89).

Direct Sub-Reports: BBNX RQD Cockpit BBNX 12M Forecast BBNX Earnings & Move BBNX Dividends & DRIP BBNX Insiders & 13F BBNX Whale Options BBNX Profit Sankey BBNX News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BBNX — Beta Bionics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Beta Bionics Inc. (BBNX) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $15.90 (-5.07% 1D, market capitalization $910.6M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -22.1%, gross margin of 55.4%, operating margin of -60.0%, and free cash flow yield of -5.88%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 12.82, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the market data, the company reports a gross margin of 55.4%. — for detailed product lines, customer segments, or revenue model descriptions.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Beta Bionics Inc. (BBNX) reported $100.3M in annual revenue (up from $65.1M in FY2024, +53.9% YoY) and -$73.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.0M revenue, -$44.1M net income) through FY2025, BBNX scaled operating cash flow to -$50.9M and free cash flow to -$56.2M, backed by $328.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.88% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $8.80 – $32.71 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded. Sector correlations and second-order bottlenecks are — Investors should note that the class action items in the news feed are the only cross-cutting event signals present in the source data.

  • Key Question #1: Can BBNX sustain or expand its -60.0% operating margin and -22.1% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $100.3M and free cash flow of -$56.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BBNX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BBNX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Beta Bionics Inc. (BBNX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBNX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBNX Bull vs. Bear Conversation Board — What's Your Call at $15.90?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBNX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BBNX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $20.27 (+21.0%)
📌 Pinned Debate

Revenue scaled from $12.0M in FY 2023 to $100.3M in FY 2025 while the forensic balance sheet scored 11 / 20 with an Altman Z of 12.82.

Revenue scaled from $12.0M in FY 2023 to $100.3M in FY 2025 while the forensic balance sheet scored 11 / 20 with an Altman Z of 12.82.. When you look under the hood at BBNX, Fundamental Cash Engine is 9/20 with 55.4% gross margins and -22.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (6/20) has been quietly accumulating below $32.71. My 12M target is $20.27.

CapAlloc_Nerd 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (55.4%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $12.90 (-23.0%)
Spot @ $16.75

Operating margin of -60% and FCF of -$56.2M in FY 2025, with ROIC at -22.1% and Insider Conviction scored 3 / 20.

Operating margin of -60% and FCF of -$56.2M in FY 2025, with ROIC at -22.1% and Insider Conviction scored 3 / 20.. Look at the math on BBNX: paying current EV/EBITDA multiples for -22.1% ROIC and -60.0% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $14.74 before getting long.

LIVE TAPE